Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | Challenges and barriers to using cancer vaccines in the clinic

Mansi Saxena • 16 Apr 2023
AACR 2023
General

Mansi Saxena, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, comments on remaining unanswered questions regarding the development of cancer vaccines. Manufacturing costs remain high due to their personalized nature, and using shared neoantigens may led to off the shelf products, reducing cost. More advanced algorithms will additionally validate potential neoantigens, but achieving durable responses will be difficult using vaccines alone. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mansi Saxena

2:31
A brief background on neoantigen vaccines
Mansi Saxena • 16 Apr 2023
4:48
PGV_001, a neoantigen vaccine, produces promising immune responses
Mansi Saxena • 16 Apr 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals